UPPSALA, SE / ACCESSWIRE / November 26, 2024 / (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec.

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Minimal residual disease testing could transform cancer care—personalized therapies, early relapse detection, and improved ...

The POLAR genomic signature can help predict the patients with early breast cancer who may benefit from adjuvant radiotherapy ...

OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements ...

Cancer, one of the most life-threatening diseases, is projected to affect over 35 million people worldwide in 2050 — 77% more ...

"Metastatic breast cancer is where breast cancer moves from the origin in the breast through the blood, and through the lymph ...

The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's ...

GRAIL (GRAL) announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer, or ...

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, ...